key: cord-0726584-x02ifm9u authors: Chen, Luke Y C; Quach, Tien T T title: COVID-19 cytokine storm syndrome: a threshold concept date: 2021-02-02 journal: Lancet Microbe DOI: 10.1016/s2666-5247(20)30223-8 sha: 2346869f7e6fbf3dec5c6c29796eb8c7f181179f doc_id: 726584 cord_uid: x02ifm9u nan The COVID-19 pandemic has placed the practice of medicine at a threshold overlooking a new and different era, 1 and has led to the evolving concept of COVID-19 cytokine storm syndrome (COVID-19-CSS). Early in the pandemic, high levels of inflammatory cytokines such as interleukin-6 (IL-6) were observed in patients with poor outcomes. Comparison with other cytokine storm syndromes, such as haemophagocytic lymphohistiocytosis (HLH), which are characterised by an excessive and deleterious immune response, led to the idea of a maladaptive immune response driving COVID-19-related morbidity and mortality. Simultaneously, support increased for testing and using immunosuppressive therapies such as cytokine blockade and JAK inhibition. 2 However, the proposition that hypercytokinaemia is pathological has been met with scepticismsuppressing the immune response to a microbial pathogen runs counter to decades of medical teaching. Critics of COVID-19-CSS posit that hypercytokinaemia might be necessary for viral clearance and observe that median IL-6 levels are low in COVID-19 compared with other inflammatory conditions, such as acute respiratory distress syndrome (ARDS) and bacterial sepsis. 3 Three lines of evidence have arisen to support the existence of COVID-19-CSS. First, several large studies have shown that IL-6 levels of more than 80 pg/mL are the best laboratory predictor of respiratory failure and death. 4 Inflammatory markers such as C-reactive protein and IL-6 are important components of prognostic models, such as the ISARIC 4C model and others. 5 In conditions for which IL-6 blockade is routinely used, such as rheumatoid arthritis and giant cell arteritis, IL-6 levels are often only modestly elevated, at less than 100 pg/mL. Second, a 2020 autopsy study 6 of 21 patients showed that many cases of lethal COVID-19 were associated with extensive multiorgan inflammation with only sporadic presence of virus. This finding suggests a maladaptive immune response, resulting in continuous neutrophil activation and organ damage. And finally, some patients with COVID-19 For more on the ISARIC 4C model see https://isaric4c.net/ outputs/4c_score/ benefit from immunosuppression. The first medication shown to reduce mortality was dexamethasone, although the pleiotropic effects of corticosteroids and insufficiency of detailed inflammatory marker data from the RECOVERY trial limit the degree to which it substantiates the CSS concept. 3, 7 More recent studies showing benefit for tocilizumab in critically ill patients and baricitinib in hospitalised patients provide more substantial evidence that some patients with COVID-19 benefit from immunosuppressive therapies. 7 Cytokine storm from viral infection is well accepted in rare diseases such Epstein-Barr virus-associated HLH (EBV-HLH). The standard of care in EBV-HLH is etoposide-based chemotherapy. Extending the umbrella of cytokine storm from rare diseases, such as EBV-HLH, to apply to some patients suffering from a pandemic illness is a new threshold concept. In education, threshold concepts are not merely core concepts, but rather induce a transformed understanding without which the learner cannot progress. 8, 9 Threshold concepts are typically applied to established principles; however, new concepts can also transform a discipline-eg, germ theory revolutionised medicine in the late 1800s, leading to aseptic technique, abandonment of ineffective concepts such as miasmas (poisoned air), and, ultimately, effective anti-microbial therapies and vaccines. 10 We provide a comparison of how both germ theory and COVID-19-CSS can be viewed as threshold concepts (table) . The concept of pathological immune activation and its therapeutic corollary, immunosuppression for the treatment of an infection, is most certainly troublesome and transformative. CSS does not apply to all patients with COVID-19. Identifying patients with immune misfiring and the most appropriate immunomodulatory therapy will require ongoing clinical trials. Given that new pandemics are certain to arise, learning how to identify and modulate maladaptive immune responses in our current liminal space is an essential learning opportunity. University of British Columbia, Vancouver, BC V5Z1M9, Canada 1 Awdish RLA. The liminal space Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study Interleukin-6 receptor antagonists in critically ill patients with COVID-19-preliminary report Grappling with troublesome knowledge Clinical education for the health professions: theory and practice From miasmas to germs: a historical approach to theories of infectious disease transmission We declare no competing interests.Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.